Back to Authors

Foote, Robert L.

https://orcid.org/0000-0003-3470-6872

Mayo Clinic

Mayo Clinic

Citations 96

Expression of PD-1 and PD-L1 in Anaplastic Thyroid Cancer Patients Treated With Multimodal Therapy: Results From a Retrospective Study
Chintakuntlawar, Ashish V. , Rumilla, Kandelaria M., Jenkins, Sarah M. , Foote, Robert L. , Kasperbauer, Jan L. , Ryder, Mabel , Alsidawi, Samer , Hilger, Crystal, Bible, Keith C. , Smith, Carin Y. , Morris, John C., Chintakuntlawar, Ashish V , Ryder, Mabel

The Journal of Clinical Endocrinology & Metabolism | April 19, 2017 | Volume: 102 | Issue: 6 | Pages: 1943-1950

10.1210/jc.2016-3756 Get It

High dose intra-arterial cisplatin with concomitant accelerated radiotherapy for patients with T4 and selected T3, N0–3, M0 head and neck cancer
Foote, Robert L. , Kasperbauer, Jan L. , Okuno, Scott H. , Nichols, D A, Brown, Paul D. , Garces, Yolanda I. , Strome, Scott E. , Sargent, Daniel J.

Journal of Clinical Oncology | April 5, 2017 | Volume: 22 | Issue: 14_suppl | Pages: 5528-5528

10.1200/jco.2004.22.90140.5528 Get It

Tobacco use among radiation oncology outpatients
Garces, Yolanda I. , Offord, Kenneth P., Croghan, Ivana T. , Decker, Paul A. , Brown, Paul D. , Clark, Matthew M. , Rummans, Teresa A. , Foote, Robert L. , Hurt, R. Douglas , Decker, Paul A.

Journal of Clinical Oncology | April 5, 2017 | Volume: 22 | Issue: 14_suppl | Pages: 1027-1027

10.1200/jco.2004.22.90140.1027 Get It

Retrospective review of adjuvant chemotherapy for esthesioneuroblastoma
Bernold, D. M., Foote, Robert L. , Link, Michael J., Moynihan, Timothy J. , Buckner, Jan C. , Khurana, Vikas , Giannini, Caterina

Journal of Clinical Oncology | February 23, 2017 | Volume: 23 | Issue: 16_suppl | Pages: 5534-5534

10.1200/jco.2005.23.16_suppl.5534 Get It

Volume-Staged Stereotactic Radiosurgery for Intracranial Arteriovenous Malformations: Outcomes Based on an 18-Year Experience
Pollock, Bruce E. , Link, Michael J. , Stafford, Scott L., Garces, Yolanda I. , Foote, Robert L. , Lanzino, Giuseppe

Neurosurgery | February 21, 2017 | Volume: 80 | Issue: 4 | Pages: 543-550

10.1093/neuros/nyw107 Get It

Abstract BACKGROUND: Radiation-based treatment options of large intracranial arteriovenous malformations (AVM) must balance the likelihood of obliteration with the risk of adverse radiation effects (ARE). OBJECTIVE: To analyze the efficacy and risks of volume-staged stereotactic radiosurgery (VS-SRS) for AVM. METHODS: Retrospective study of 34 AVM patients having VS-SRS between 1997 and 2012. A median of 2 stages (range, 2-4) was used to treat a median AVM volume of 22.2 cm 3 (range, 7.4-56.7). The median AVM margin dose was 16 Gy (range, 14-18); the median radiosurgery-based AVM score was 2.81 (range, 1.54-6.45). The median follow-up after VS-SRS was 8.2 years (range, 3-13.3). RESULTS: Nidus obliteration was noted in 18 patients (53%) after VS-SRS. The rate of obliteration was 14% at 3 years, 54% at 5 years, and 75% at 7 years. Six patients (18%) had 11 bleeds after VS-SRS. Two patients (6%) remained neurologically stable, 2 (6%) patients had significant deficits, and 2 patients (6%) died. The actuarial risk of a first bleed after VS-SRS was 6% at 1 year, 12% at 3 years, and 19% at 7 years. Six patients (18%) underwent repeat SRS; all achieved nidus obliteration for an overall cure rate of 71%. Two patients (6%) had a permanent ARE after VS-SRS or repeat SRS. CONCLUSION: VS-SRS permitted large volume intracranial AVM to be treated with a low rate of ARE. Further study is needed on dose escalation and decreasing the treatment volume per stage to determine if this will increase the rate of obliteration with this technique.
Survey of Current Practices from the International Stereotactic Body Radiotherapy Consortium (Isbrtc) for Head and Neck Cancers
Karam, Irene , Yao, Min , Heron, Dwight E. , Poon, Ian , Koyfman, Shlomo A. , Yom, Sue S. , Siddiqui, Farzan , Lartigau, Éric, Cengiz, Mustafa , Yamazaki, Hideya , Hara, Wendy, Phan, Jack , Vargo, John A. , Lee, Victor , Foote, Robert L. , Harter, K. William, Lee, Nancy Y. , Sahgal, Arjun , Lo, Simon S. , Yom, Sue S , Phan, Jack

Future Oncology | November 15, 2016 | Volume: 13 | Issue: 7 | Pages: 603-613

10.2217/fon-2016-0403 Get It

Stereotactic Radiosurgery for Cystic Vestibular Schwannomas
Frisch, Christopher D., Jacob, Jeffrey T. , Carlson, Matthew L. , Foote, Robert L. , Driscoll, Colin L. W., Neff, Brian A., Pollock, Bruce E. , Link, Michael J.

Neurosurgery | August 10, 2016 | Volume: 80 | Issue: 1 | Pages: 112-118

10.1227/neu.0000000000001376 Get It

Abstract BACKGROUND: The optimum treatment for cystic vestibular schwannoma (VS) remains controversial. Anecdotally, many treating physicians feel that cystic VSs do not respond to stereotactic radiosurgery (SRS) as well as noncystic tumors. OBJECTIVE: To present outcomes after treatment of predominantly cystic VS with SRS. METHODS: A prospectively maintained clinical database of patients undergoing Gamma Knife (Elekta Instruments, Stockholm, Sweden) radiosurgery (GKRS) for VS at a single tertiary academic referral center was retrospectively reviewed. Patients diagnosed with cystic VS who were treated with GKRS between 1997 and 2014 were analyzed. Size-matched solid tumors treated with GKRS during this period were selected as controls. RESULTS: Twenty patients (12 women; median age at treatment, 56 years; range, 36-85 years) with cystic VS met inclusion criteria. The median radiologic follow-up within the cystic group was 63 months (range, 17-201 months), and the median change in tumor size was −4.9 mm (range, −10.4 to 9.3 mm). Sixteen tumors (80%) shrank, 2 (10%) remained stable, and 2 (10%) enlarged, accounting for a tumor control rate of 90%. The median radiologic follow-up in the noncystic control group was 67 months (range, 6-141 months), and the median change in size was −2.0 mm (range, −10.4 to 2.5 mm). Tumor control in the solid group was 90%. Comparing only those tumors that decreased in size showed that there was a trend toward a greater reduction within the cystic group ( P = .05). CONCLUSION: The present study demonstrates that tumor control after SRS for cystic VS may not differ from that of noncystic VS in selected cases.
Establishing quality indicators for neck dissection: Correlating the number of lymph nodes with oncologic outcomes (NRG Oncology RTOG 9501 and RTOG 0234)
Divi, Vasu , Harari, Paul M. , Cooper, Jay S., McHugh, Jonathan B. , Bell, Diana , Cmelak, Anthony J. , Suntharalingam, Mohan, Raben, David, Kim, Harold , Spencer, Sharon A., Laramore, George E. , Trotti, Andy, Foote, Robert L. , Schultz, Christopher J. , Le, Quynh‐Thu , Harris, Jonathan , Sturgis, Erich M. , Thorstad, Wade , Zhang, Qiang , Holsinger, F. Christopher , Kim, Harold E , Le, Quynh-Thu

Cancer | July 15, 2016 | Volume: 122 | Issue: 22 | Pages: 3464-3471

10.1002/cncr.30204 Get It

BACKGROUNDProspective quality metrics for neck dissection have not been established for patients with head and neck squamous cell carcinoma. The purpose of this study was to investigate the association between lymph node counts from neck dissection, local‐regional recurrence, and overall survival.METHODSThe number of lymph nodes counted from neck dissection in patients treated in 2 NRG Oncology trials (Radiation Therapy Oncology Group [RTOG] 9501 and RTOG 0234) was evaluated for its prognostic impact on overall survival with a multivariate Cox model adjusted for demographic, tumor, and lymph node data and stratified by the postoperative treatment group.RESULTSFive hundred seventy‐two patients were analyzed at a median follow‐up of 8 years. Ninety‐eight percent of the patients were pathologically N+. The median numbers of lymph nodes recorded on the left and right sides were 24 and 25, respectively. The identification of fewer than 18 nodes was associated with worse overall survival in comparison with 18 or more nodes (hazard ratio [HR], 1.38; 95% confidence interval [CI], 1.09‐1.74; P = .007). The difference appeared to be driven by local‐regional failure (HR, 1.46; 95% CI, 1.02‐2.08; P = .04) but not by distant metastases (HR, 1.08; 95% CI, 0.77‐1.53; P = .65). When the analysis was limited to NRG Oncology RTOG 0234 patients, adding the p16 status to the model did not affect the HR for dissected nodes, and the effect of nodes did not differ with the p16 status.CONCLUSIONSThe removal and identification of 18 or more lymph nodes was associated with improved overall survival and lower rates of local‐regional failure, and this should be further evaluated as a measure of quality in neck dissections for mucosal squamous cell carcinoma. Cancer 2016;122:3464–71. © 2016 American Cancer Society.
Head and Neck Soft Tissue Sarcomas Treated with Radiation Therapy
Vitzthum, Lucas K. , Brown, Lindsay C. , Rooney, Jessica, Foote, Robert L. , Rooney, Jessica W

Rare Tumors | June 29, 2016 | Volume: 8 | Issue: 2 | Pages: 60-65

10.4081/rt.2016.6165 Get It

Head and neck soft tissue sarcomas (HNSTSs) are rare and heterogeneous cancers in which radiation therapy (RT) has an important role in local tumor control (LC). The purpose of this study was to evaluate outcomes and patterns of treatment failure in patients with HNSTS treated with RT. A retrospective review was performed of adult patients with HNSTS treated with RT from January 1, 1998, to December 31, 2012. LC, locoregional control (LRC), disease-free survival (DFS), overall survival (OS), and predictors thereof were assessed. Forty-eight patients with HNSTS were evaluated. Five-year Kaplan-Meier estimates of LC, LRC, DFS, and OS were 87, 73, 63, and 83%, respectively. Angiosarcomas were found to be associated with worse LC, LRC, DFS, and OS. Patients over the age of 60 had lower rates of DFS. HNSTSs comprise a diverse group of tumors that can be managed with various treatment regimens involving RT. Angiosarcomas have higher recurrence and mortality rates.
Comparative analysis of arteriovenous malformation grading scales in predicting outcomes after stereotactic radiosurgery
Pollock, Bruce E. , Storlie, Curtis B. , Link, Michael J. , Stafford, Scott L., Garces, Yolanda I. , Foote, Robert L.

Journal of Neurosurgery | April 9, 2016 | Volume: 126 | Issue: 3 | Pages: 852-858

10.3171/2015.11.jns151300 Get It

OBJECTIVE Successful stereotactic radiosurgery (SRS) for the treatment of arteriovenous malformations (AVMs) results in nidus obliteration without new neurological deficits related to either intracranial hemorrhage (ICH) or radiation-induced complications (RICs). In this study the authors compared 5 AVM grading scales (Spetzler-Martin grading scale, radiosurgery-based AVM score [RBAS], Heidelberg score, Virginia Radiosurgery AVM Scale [VRAS], and proton radiosurgery AVM scale [PRAS]) at predicting outcomes after SRS. METHODS The study group consisted of 381 patients with sporadic AVMs who underwent Gamma Knife SRS between January 1990 and December 2009; none of the patients underwent prior radiation therapy. The primary end point was AVM obliteration without a decline in modified Rankin Scale (mRS) score (excellent outcome). Comparison of the area under the receiver operating characteristic curve (AUC) and accuracy was performed between the AVM grading scales and the best linear regression model (generalized linear model, elastic net [GLMnet]). RESULTS The median radiological follow-up after initial SRS was 77 months; the median clinical follow-up was 93 months. AVM obliteration was documented in 297 patients (78.0%). Obliteration was 59% at 4 years and 85% at 8 years. Fifty-five patients (14.4%) had a decline in mRS score secondary to RICs (n = 29, 7.6%) or ICH (n = 26, 6.8%). The mRS score declined by 10% at 4 years and 15% at 8 years. Overall, 274 patients (71.9%) had excellent outcomes. There was no difference between the AUC for the GLMnet (0.69 [95% CI 0.64–0.75]), RBAS (0.68 [95% CI 0.62–0.74]), or PRAS (0.69 [95% CI 0.62–0.74]). Pairwise comparison for accuracy showed no difference between the GLMnet and the RBAS (p = 0.08) or PRAS (p = 0.16), but it did show a significant difference between the GLMnet and the Spetzler-Martin grading system (p < 0.001), Heidelberg score (p < 0.001), and the VRAS (p < 0.001). The RBAS and the PRAS were more accurate when compared with the Spetzler-Martin grading scale (p = 0.03 and p = 0.01), Heidelberg score (p = 0.02 and p = 0.02), and VRAS (p = 0.03 and p = 0.02). CONCLUSIONS SRS provides AVM obliteration without functional decline in the majority of treated patients. AVM grading scales having continuous scores (RBAS and PRAS) outperformed integer-based grading systems in the prediction of AVM obliteration without mRS score decline after SRS.